A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

← catalyst calendar

NCT06412666 · readout ≤ 1,261 d

Sponsored by Cytokinetics (industry) · CYTK — their whole pipeline →. With Bayer.

Phase

Phase 2/3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

65estimated

Sites

Countries

Canada, Italy, Japan +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-05-29

actual

When the study began enrolling

Primary completion

Jan 2030

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2030

estimated

The whole study's end, after follow-up

First posted

2024-05-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventions

Drug: Aficamten
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G)

measured Baseline to week 12 (Period 1)

Publications

PMID 41347307 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CYTK's whole pipeline · Catalyst calendar · Every registered study · What changed